Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry

Abstract

Background Real‐world data describing outcomes of treatment among metastatic renal cell carcinoma (mRCC) patients are limited and heterogeneous. Aim RENSUR3 registry study assessed real‐world data on the use of therapies in mRCC and overall survival (OS) in Russia, Kazakhstan, and Belarus. Methods Patients were included in the retrospective multicenter registry study. To be eligible, patients were required to have mRCC diagnosed from January 2015 to January 2016. Anonymized data were collected through an online registry. The outcomes of interest were patient characteristics, treatment patterns, and OS. Results 1094 mRCC patients were identified. Mean age was 62.3 (SD, 11.2) years. Four hundred and forty‐four (41%) patients were 65 years and older. Primary tumor has not been removed in 503 (46%) patients. Subtype of RCC based on WHO classification (clear‐cell or other) has been reported in 402 (37%) patients. In total, 595 (54.4%) patients received systemic therapy for metastatic disease. 58% of elderly patients (≥65) were not treated compared to 37% of younger patients. Cytokines and targeted therapy were used in 298 (50.1%) and 297 (49.9%) of 595 treated patients, respectively. Median OS was 11.9 months (95% CI 10.9‐12.9). The 1‐ and 3‐year OS rates were 49.6% and 19.3%. Conclusions Half of patients received no systemic therapy or had only cytokines for mRCC in Russia, Kazakhstan, and Belarus, which doubtless negatively affected OS in this population. Novel therapies should be considered as life prolonging and a priority.

Construction and validation of a novel prognostic nomogram for patients with metastatic renal cell carcinoma: a SEER-based study

“…In recent decades, multiple scholars have reported that lymph node invasion is a significant risk factor for survival in patients with MRCC. 5 , 21 In the present study, the roles of lymph node status in our constructed nomograms were consistent with those in previous reports, and the multivariable Cox regression model showed that N stage was inversely related to patient prognosis. Currently, there are limited reports regarding the specific number and location of metastatic sites in patients with MRCC.…”

“… 18 In addition, among patients with MRCC, those with clear cell carcinoma had a better prognosis than patients with non-clear cell carcinoma (31 vs. 24 months) in the multicenter Korean registry. 5 Similar to our result, patients with clear cell carcinoma exhibited a better prognosis than patients with non-clear cell carcinoma tissue types. Moreover, compared with clear cell carcinoma, collecting duct carcinoma and sarcomatoid dedifferentiation tissue types were significantly related to a worse prognosis according to our constructed nomogram.…”

“… 17 In the RENSUR3 study, the median survival time of patients with MRCC in the entire cohort was 11.9 months. 5 In India and Brazil, the median survival times were 12.87 months and 14.1 months, respectively. 5 Similarly, the median survival time was 11 months for patients with MRCC from the SEER database.…”

“… 5 In India and Brazil, the median survival times were 12.87 months and 14.1 months, respectively. 5 Similarly, the median survival time was 11 months for patients with MRCC from the SEER database. Given the poor prognosis of patients with MRCC, the medical community is now paying more attention to clinical prognostic evaluation and individualized therapeutic management.…”

“… 3 Owing to the poor prognosis of patients with MRCC and the median survival of 4 to 20 months, more active management for these patients is needed. 4 – 5 …”